Skip to content
About the Association
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Community Commitment
Careers
Contact Us
About the Association
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Community Commitment
Careers
Contact Us
Resources
2025 Savings Report
2025 Advocacy Priorities
2025 First Generics White Paper
Drug Shortages White Paper
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Blog
Founders Blogs
Amicus Briefs
Patient Stories
Resources
2025 Savings Report
2025 Advocacy Priorities
2025 First Generics White Paper
Drug Shortages White Paper
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Blog
Founders Blogs
Amicus Briefs
Patient Stories
Advocacy
Federal Advocacy
Biosimilars
GDUFA/BsUFA User Fees
Inflation Reduction Act
Intellectual Property & Patent Reform
Medicaid Generics Penalty
State Advocacy
Tariffs & Trade
Events
Access! 2026
GRx+Biosims 2026
Press Releases
JOIN
Advocacy
Federal Advocacy
Biosimilars
GDUFA/BsUFA User Fees
Inflation Reduction Act
Intellectual Property & Patent Reform
Medicaid Generics Penalty
State Advocacy
Tariffs & Trade
Events
Access! 2026
GRx+Biosims 2026
Press Releases
JOIN
SideMenu
Home
Blog
Biosimilars Council Press Releases
Blog
Blog
February 24, 2023
AAM
A Look Back at Access! 2023
Blog
February 9, 2023
AAM
The Quickest Route to U.S. Essential Medicines Production: Existing and Idle Production Sites
Blog
January 5, 2023
AAM
Desi is Back Playing Soccer and Doing “Normal Kid” Stuff
Blog
January 3, 2023
AAM
Generics and Biosimilars Offer Savings for Patients Fighting Cancer, Heart Disease and Other Conditions
Blog
December 21, 2022
AAM
Ensuring Patient Access to Amoxicillin When Demand is High
Blog
November 23, 2022
AAM
Back Together: GRx+Biosims 2022 Conference Recap
Blog
October 19, 2022
AAM
Patients Pay More When Generic Drugs Are Placed On Non-Generic Tiers, Even Though Prices For Generics Are Going Down
Blog
October 14, 2022
AAM
Member Spotlight: Meitheal Pharmaceuticals
Blog
October 3, 2022
AAM
Generics & Biosimilars Continue to Reward Patients, Employers and Taxpayers
Blog
September 29, 2022
AAM
October Can Now Afford to do More to Support Her Mental Health
Blog
September 6, 2022
AAM
Explosive Growth in Drug Discount Cards is a Symptom of a Broken System
Blog
July 28, 2022
AAM
AAM All Access Podcast: Medicare Drug Price Negotiation is Bad for Patients
Load More
Resources
2025 Savings Report
2025 Advocacy Priorities
2025 First Generics White Paper
Drug Shortages White Paper
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Blog
Founders Blogs
Amicus Briefs
Patient Stories
About the Association
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Community Commitment
Careers
Contact Us
Advocacy
Federal Advocacy
Biosimilars
GDUFA/BsUFA User Fees
Inflation Reduction Act
Intellectual Property & Patent Reform
Medicaid Generics Penalty
State Advocacy
Tariffs & Trade
Events
Access! 2026
GRx+Biosims 2026
Press Releases
JOIN
About the Association
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Community Commitment
Careers
Contact Us
Resources
2025 Savings Report
2025 Advocacy Priorities
2025 First Generics White Paper
Drug Shortages White Paper
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Blog
Founders Blogs
Amicus Briefs
Patient Stories
Advocacy
Federal Advocacy
Biosimilars
GDUFA/BsUFA User Fees
Inflation Reduction Act
Intellectual Property & Patent Reform
Medicaid Generics Penalty
State Advocacy
Tariffs & Trade
Events
Access! 2026
GRx+Biosims 2026
Press Releases
JOIN
